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ABSTRACT 
 
Reactive oxygen species (ROS) are important molecules that regulate 
several physiological processes, and excessive levels can contribute to 
tumorigenesis. In cancer, the PI3K/Akt pathway is associated with the increase of 
ROS; maybe to act as signaling messengers of other molecules that integrate this 
important pathway. One of the genes that are transcriptionally activated by PI3K/Akt 
is HOXA9. We consider that HOXA9 could be contributing for ROS production in the 
PI3K/Akt pathway. To investigate this, intracellular ROS levels were measured in 
human GBM cell line (U87MG) and in immortalized human astrocytes 
(hTERT/E6/E7), both with HOXA9 overexpression as well as in their control cells. 
Hydrogen peroxide was used as an exogenous source of ROS and its functional 
effects were studied by the assessment of cell viability. Since, cancer cells rely 
mostly on aerobic glycolysis to satisfy their energetic demands and to decrease ROS 
levels, it was also investigated the metabolic profile mediated by HOXA9. Ultimately, 
by submitting the previous cell lines and additionally the A172 cell line to a PI3K 
inhibitor, it was possible to evaluate the role of HOXA9 regarding ROS production in 
the PI3K/Akt pathway. The results showed that HOXA9 overexpression is associated 
with the increase of ROS production in the U87MG cell line. This increase in ROS 
production is parallel to a lower glycolytic profile present by the U87MG-HOXA9 cell 
line, which produced less lactate comparing to the U87MG-MSCV control cell line. 
Also, ROS accumulation accompanied U87MG-HOXA9 cell line resistance after 
challenges with hydrogen peroxide. Conversely, we also show that exposure of 
U87MG-HOXA9 cells to PI-103, an inhibitor of the PI3K pathway, results in the 
inhibition of the pathway, decrease HOXA9 expression, and enhance ROS levels. 
Thus, this study provides more understanding about the regulatory role of HOXA9 for 
ROS production in the PI3K/Akt pathway, pointing this gene as a possible 
responsible for ROS generation in this pathway. Importantly, the resistance to 
oxidative stress mediated by HOXA9 in GBM cells could be relevant to the 
understanding of therapy resistance, since ROS are associated with resistance to 
clinical alkylatant agents in glioma cells. 
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RESUMO 
 
Espécies reativas de oxigénio (ERO) são moléculas importantes que regulam 
vários processos fisiológicos, e em excesso podem contribuir para a tumorigénese. 
No cancro, a via da PI3K/Akt está associada com o aumento de ERO; possivelmente 
com a função de atuarem como mensageiros na sinalização de outras moléculas 
que integram esta importante via. Um dos genes que é transcricionalmente ativado 
pela via da PI3K/Akt é o HOXA9. Neste trabalho, pretende-se avaliar a contribuição 
do HOXA9 na produção de ERO na via da PI3K/Akt. Para isso, foram avaliados os 
níveis intracelulares de ERO em linhas celulares derivadas de células de 
glioblastoma (U87MG) e em astrócitos humanos imortalizados (hTERT/E6/E7), 
ambas com sobre-expressão de HOXA9, bem como em células controlo HOXA9-
negativas. O peróxido de hidrogénio foi usado como uma fonte exógena de ERO, e 
os seus efeitos funcionais foram avaliados através da viabilidade celular. Uma vez 
que, as células tumorais dependem maioritariamente da glicólise aeróbica para 
satisfazerem as suas necessidades energéticas e para diminuírem os seus níveis de 
ERO, foi também investigado o perfil celular metabólico mediado pelo HOXA9. Por 
fim, ao submeter as linhas celulares anteriores e adicionalmente a linha A172 a um 
inibidor da via da PI3K foi possível estudar o papel do HOXA9 no que concerne à 
produção de ERO nesta via. Os resultados obtidos mostraram que a sobre-
expressão do HOXA9 está associada a um aumento dos níveis de ERO na linha 
celular U87MG. Este aumento de ERO é paralelo a um perfil glicolítico mais 
reduzido apresentado pelas células da linha celular U87MG-HOXA9, que se 
caracteriza pela baixa produção de lactato comparativamente com a sua linha 
celular controlo U87MG-MSCV. Ainda, a acumulação de ERO foi acompanhada pela 
resistência da linha U87MG-HOXA9 após tratamentos com peróxido de hidrogénio. 
Por outro lado, também foi demonstrado que a exposição das células U87MG-
HOXA9 ao PI-103, um inibidor da via PI3K, resultou na inibição da via, na diminuição 
da expressão do HOXA9, e no aumento dos níveis de ERO. Assim, este estudo 
fornece uma melhor compreensão sobre o papel do HOXA9 na produção de ERO na 
via PI3K/Akt, sugerindo este gene como um possível responsável pela produção de 
ERO nesta via. Ainda, é de realçar que a resistência ao stress oxidativo mediado 
pelo HOXA9 em células glioblastoma pode ser relevante para a compreensão da 
resistência à terapia, uma vez que as ERO estão associadas a uma resistência ao 
tratamento com agentes alquilantes em células de glioma. 
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INTRODUCTION 
 
1 GLIOMAS: an overview 
 
Tumors of the Central Nervous System (CNS) represent only about 2% of all 
human tumors1. However, they are an important cause of morbidity and mortality in 
both children and adults, being the first and the fourth leading cause of cancer-
related death in children and in middle-aged adults, respectively2. The global annual 
incidence of primary brain tumors is about 5 to 10 cases per 100,000 persons. 
According to World Health Organization (WHO), Portugal stands as one of the 
countries with the highest incidence of this type of tumors, where 989 new cases of 
nervous system tumors were diagnosed in 2008, with 753 related deaths3. 
Associated with the CNS are several types of primary brain tumors, being 
gliomas the most comum4, 5, 6, representing about 80% with a lower rate of survival7. 
Glioma designation arises from their cellular origin; they are glial-derived cells, 
including astrocytes, oligodendrocytes and ependymal cells8, 9. Depending on the cell 
type of origin, gliomas are divided into four major histological types: astrocytic (Table 
I), oligodendroglial, mixed oligoastrocytic tumors and ependymonas8, 9. According to 
the WHO classification system, gliomas can be classified into four grades of 
malignancy (I-IV)10, 11, 12: grade I (pilocytic astrocytoma), grade II (diffuse 
astrocytoma), grade III (anaplastic astrocytoma) and grade IV (glioblastoma - GBM). 
Grade I gliomas correspond to those with a benign behavior and therefore are less 
aggressive, while grades II-IV correspond to malignant and more aggressive 
gliomas8. Among differential grading, GBM stands as the most prevalent, accounting 
for 60-70%11,13, and deadly malignant glioma. 
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Table I. WHO classification of astrocytic tumors8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1 Glioblastoma 
 
1.1.1 Etiological and molecular basis of Glioblastoma 
 
Little is known about GBM etiology. Exposure to ionizing radiation, rare 
mutations of penetrant genes, and inherited susceptibility represent a reduced 
portion of some proposed risk factors10, 14. Nevertheless, during the last decade there 
have been significant advances in understanding the molecular profiles of GBMs. 
The malignant glioma arises from sequential accumulation of genetic aberrations and 
deregulation of growth factors signaling pathways8, 15 (Figure 1). GBMs can be 
separated into two main types based on biological and genetic differences8: primary 
(de novo) and secondary GBMs. Primary GBMs typically occur in patients older than 
50 years and are characterized by amplification and mutations in Epidermal Growth 
Factor Receptor (EGFR). The amplification of the EGFR gene in chromosome 7 
occurs in about 40% of the GBM10, 16, and appears to be a late event in the 
development of malignant astrocytomas, often followed by gene rearrangements 
which result in deletions of certain portions encoding the protein. The most frequent 
GBM molecular rearrangement involves the deletion of EGFR exons and it occurs in 
a large fraction of de novo GBMs, but it is not frequently observed in progressive (or 
secondary) tumors. Loss of heterozygosis (LOH) of chromosome 10q, deletion of the 
1 Astrocytic tumors 
   1.1 Astrocytoma                                                                              WHO Grade II 
         1.1.1 Fibrilar                                                                              WHO Grade II 
         1.1.2 Protoplasmic                                                                    WHO Grade II 
         1.1.3 Gemistocytic                                                                    WHO Grade II 
  1.2 Anaplastic Astrocytoma                                                            WHO Grade III 
   1.3 Glioblastoma                                                                             WHO Grade IV 
         1.3.1 Giant cells Glioblastoma                                                  WHO Grade IV 
         1.3.2 Gliosarcoma                                                                     WHO Grade IV 
   1.4 Pilocytic Astrocytoma                                                                WHO Grade I 
   1.5 Pleomorphic Xanthoastrocytoma                                               WHO Grade II 
   1.6 Subependymal giant cell astrocytoma                                       WHO Grade I 
                                      Influence of HOXA9 expression in the PI3K-mediated oxidative stress in GBM 
! 3!
p16 gene and deletion of Phosphatase and Tensin homologue (PTEN) are also 
changes that occur in primary GBMs. LOH of chromosome 10q includes the PTEN 
gene (chromosomal region 10q23.3), and is one of the most common genetic defects 
found in GBM, occurring in about 70-90% of tumors17, 18,19. There are evidences to 
suggest that the mutation of the PTEN gene is a marker for a poor prognosis in 
patients with gliomas19. Moreover, the secondary GBMs alterations occur in young 
patients, and develop from low-grade gliomas or anaplastic astrocytomas, 
progressing after a period of several years into GBM. These tumors, which are much 
less common than primary GBMs, are characterized by mutations in the TP538, 20, 21, 
overexpression of the Platelet-derived growth factor receptor (PDGFR) gene, 
alterations in Rb and p16 pathways, and LOH of chromosome 10q8, 22. TP53 is an 
important tumor suppressor gene, and is mapped on chromosome 17p region, a 
region of frequent deletion in GBMs. In response to various stresses, this can trigger 
various biological functions at the level of the cell cycle, apoptosis, differentiation and 
angiogenesis20, 21. While TP53 mutations are rare in primary GBMs (<10%), they are 
common in secondary GBMs (<65%), and in 90% of cases the mutation was already 
present in the first biopsy20. The main consequence of functional TP53 mutations is 
the loss of specificity of DNA binding and transcriptional activity23. 
Despite their genetic differences, primary and secondary GBMs are 
morphologically indistinguishable and respond similarly to conventional therapy. 
However, they may react differently to molecular-targeted therapies8. 
Genetic alterations have been identified by being important in the development and 
proliferation of malignant characteristics that are associated with GBM. Some of 
these genetic aberrations appear to have prognostic significance. Nonetheless, 
knowledge of these provides clues for the identification of signaling pathways 
responsible for carcinogenesis, as well as potential therapeutic agents15. However, 
despite a huge progress in the genomic characterization of GBM, it still has no 
effective translation value. 
!!!!! !
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Figure 1. Summary of genetic and chromosomal alterations involved in the 
development of primary and secondary GBMs. The transcription factor Olig2 
(blue) and vascular endothelial growth factor (VEGF, red) are virtually expressed in 
all high-grade gliomas. The median survival (asterisk) is shown (Adapted from 
Kleihues P8). 
 
 
1.1.2 Therapy and outcomes 
 
Without doubt, GMB is the main responsible for overall shorter survival in 
CNS tumors. Despite clinical efforts, the prognosis of patients remains dismal, with a 
median survival after diagnosis of approximately 12-15 months4. Its highly infiltrative 
growth, very aggressive nature, relative resistance to radiotherapy and 
chemotherapy treatments8, and relentless recurrence are the main features of GBM 
patient’s poor survival. Behind these features are already known GBM biological 
hallmarks such as uncontrolled cellular proliferation, resistance to apoptosis, 
Olig2  expression (100%) 
TP53 mutation (>65%) 
PDGFA/PDGFR-α overexpression (~60%) 
Low-grade astrocytoma (5–10 years)* 
(WHO Grade II) 
LOH 19q (~50%) 
RB mutation (~25%) 
CDK4 amplification (15%) 
MDM2 overexpression (10%) 
P16Ink4a/P14ARF loss (4%) 
LOH 11p (~30%) 
Anaplastic Astrocytoma (2–3 years)* 
(WHO Grade III) 
 
LOH 10q (~70%) 
DCC loss (~50%) 
PDGFR-α amplification (~10%) 
PTEN mutation (~10%) 
PI3K mutation/amplification (~10%) 
VEGF overexpression 
Secondary GBM (12–15 months)* 
(WHO Grade IV) 
Olig2 expression (100%)  
EGFR amplification (~40%) 
EGFR overexpression (~60%) 
EGFR mutation (~20–30%) 
MDM2 amplification (~10%) 
MDM2 overexpression (>50%) 
LOH 10q (~70%) 
P16Ink4a/P14ARF loss (~30%) 
PTEN mutation (~40%) 
PI3K mutation/amplification (~20%) 
RB mutation 
VEGF overexpression 
Primary GBM (12–15 months)* 
(WHO Grade IV) 
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genomic instability, invasion, angiogenesis, and tumor-initiating cells24. It is important 
to notice that their diffuse and infiltrative growth pattern becomes a clinical challenge 
by preventing complete surgical removal. Taken all these factors together there is an 
understanding of the unquestionable difficulty to improve the disease outcome. 
Actually, even with the current standard of care, which includes surgical resection 
safely feasible, followed by chemoradiotherapy with concurrent temozolomide (TMZ), 
and then adjuvant chemotherapy with TMZ, most of the patients die after two years15; 
reason why the standard treatment is still far from the ideal. Therefore, there is an 
urgent need to identify molecular markers; a better tumor classification and patients 
stratification into clinically-relevant prognostic subgroups would be a new framework 
to treat GBM. Already established GBM markers are: age at diagnosis25, 26, 
Karnofsky Performance Status26, 27, 28, and extent of surgical resection28. Although 
they are important clinical factors, they are not enough as GBM prognostic markers, 
opening the path for a challenging discovery of new biomarkers with significant 
impact in prognosis or in prediction of response to specific therapies. Currently, one 
of the promising prognostic biomarker for patients with GBM is the methylation status 
of O6-methylguanine methyltransferase (MGMT) promotor29; its methylation is 
predictive of a response of GBM patients to treatment30, being associated with 
prolonged survival in patients with GBM who receive alkylating chemotherapy. 
 
1.1.3 HOXA9: a potential Glioblastoma biomarker 
 
In an attempt to search for new prognostic biomarkers in GBM, recent studies 
highlight the importance of the Homeobox (HOX)-containing genes, particularly the 
HOXA cluster, reported to be aberrantly expressed in GBMs31, 32, 33, 34. HOX genes 
constitute a gene family that encode specific nuclear proteins (homeoproteins) that 
act as transcription factors35, 36, which play an important role during normal 
development by regulating primary cellular processes, such as cell identity, cell 
division and differentiation36. In humans, HOX genes are known to have a unique 
genomic organization; they are distributed in four genomic clusters, each localized on 
a different chromosome (HOXA at 7p15.3, HOXB at 17p21.3, HOXC at 12q13.3 and 
HOXD at 2q31)37. These remarkable evolutionarily conserved genes have been the 
topic of various cancer-related studies due to its aberrant expression in many solid 
tumors38, 39 and leukemia40, 41, 42. Among all HOXA genes, HOXA9 was found to be 
overexpressed in myeloid leukemogenesis40 and to be involved in the regulation of 
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leukemogenic pathways by potentially activating and repressing several oncogenes 
and tumor suppressor genes, respectively. Also, it was associated with poor 
prognosis in patients with acute myeloid leukemia43. HOXA9 seems to play 
significant roles in other malignancies besides leukemia, such as ovarian44, 45 and 
breast46 cancer. In GBM, HOXA9 emerged as the only aberrantly expressed HOX 
gene associated with poor patient outcome and shorter survival32. Additionally, in 
vitro studies showed that HOXA9 has pro-proliferative and anti-apoptotic properties. 
Importantly, it was also reported that HOXA9 transcriptional activation is regulated by 
phosphatidylinositol 3-kinase (PI3K) pathway through reversible epigenetic 
modifications32. Also, HOXA9 expression was shown to be associated with shorter 
survival of pediatric high-grade gliomas33. Taken all together, it is no surprise the 
emergent interest in the study of HOXA9 gene. 
 
2 OXIDATIVE STRESS IN GLIOBLASTOMA  
 
GBM are notorious by their aggressiveness and resistance to radiotherapy 
and chemotherapy8. A huge number of studies are developed in a tentative to 
understand and overcome GBM remarkable resistance to cell death24. Among 
several proposed molecules and altered pathways, oxidative stress, implicated in the 
etiology of cancer47, 48, 49, plays a significant role in the development and resistance of 
gliomas50. 
 
2.1 Reactive oxygen species: definition and sources 
Reactive oxygen species (ROS) is a collective term used to describe a 
heterogeneous group of oxygen (O2)-derived free radicals, including superoxide 
anion (O2•−), hydroxyl (HO•), peroxyl (RO2•) and alkoxyl (RO•) radicals, as well as 
non-radical species including molecules like hydrogen peroxide (H2O2), hypochlorous 
acid (HOCl), oxygen (O2) and peroxynitrite (ONOO-)51, 52, also capable of generating 
free radicals. By definition, a free radical is a molecule, which contains one or more 
unpaired electrons in its outer orbital53. 
Although O2 is a requirement of all aerobic organisms for their energy 
production, it is also a source of ROS51. In fact, most of the energy that aerobic cells 
need to live depends on oxidative phosphorylation49 - a mitochondrial process that 
requires O2 by which inevitably ROS are generated mainly due to the incomplete 
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reduction of O2 by the electron transfer chain (ETC) system in the mitochondria54, 55; 
therefore, ROS are a normal byproduct of cellular metabolic processes. Mitochondria 
are considered the major source of intracellular ROS56, where in normal conditions it 
is estimated that 1–2% of the O2 consumed by mitochondria is converted to ROS52, 56, 
57. However, this is not a mitochondrial exclusive process; other organelles, such as 
peroxisomes58 and the endoplasmic reticulum59, as well as external sources such as 
UV radiation, toxic chemicals and drugs60, and the enzyme NADPH oxidase61, can 
also contribute to ROS generation. ROS production begins with the “leaky” transfer 
of a single electron to O2, mainly at ETC complex I and III54, 55, resulting in its partial 
reduction and consequent generation of O2•−. A wide of a variety of potential 
chemical reactions lies at O2•−, setting it as the precursor to other major forms of 
ROS62. Although there are evidences that O2•− may enter the cytosol through 
specialized mitochondrial channels, such as the voltage-gated anion channel63, due 
to its negative charge O2•− that does not diffuse freely across membranes and 
therefore needs to be converted into ROS membrane permeable molecules. Thus, 
O2•− can be converted to H2O2 and O2 by the enzyme manganese superoxide 
dismutase (SOD)62. H2O2 can be further transformed either via Fenton reactions or 
by enzymatic catalysis to several highly oxidizing derivatives including HO• radicals 
and HOCl64, 65. 
 
 
 
 
 
 
 
 
Figure 2. Schematic representation of physiologic ROS. 
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2.2 Dual role of reactive oxygen species 
It is well known that ROS play a dual role by acting as both key components 
of many normal physiological processes66 and as a deleterious cellular stimulus67. 
This double-edged sword has major implications in the cell path, and its modulation 
is dependent on the levels of ROS produced in the cell49, 68, 69. On the one hand, 
appropriate low levels of ROS participate in the maintenance of cellular homeostasis. 
On the other hand, overproduction of ROS, as well as a defective antioxidant system, 
leads to the accumulation of oxidative stress, potentiating the onset of oxidative-
related diseases. The damaging effect of ROS is due to its capacity to interact with 
all biological macromolecules, such as lipids, proteins and nucleic acids, by 
modifying both their structure and function, ultimately oxidizing and damaging them68. 
Its no surprise that cells have developed ways to control the continuous flux of ROS 
and prevent oxidative stress. These systems are well studied non-enzymatic and 
enzymatic antioxidizing agents, namely: glutathione70, SOD71, catalase72 and 
peroxiredoxin73. The antioxidant process is a result of an interplay of the antioxidants 
components; for example, SOD present both in the cytosol and in mitochondria, 
converts superoxide into H2O261, which is further detoxified into H2O and O2 by 
catalase72 or peroxidases, such as the glutathione peroxidase, which is the main 
redox agent of the cell70. In addition, other molecules such as cytochrome C have an 
important antioxidant function by acting as a powerful O2− scavenger in the 
intermembrane space of mitochondria49. However, as is evident, more work is 
required to better understand the role of ROS in tumor progression.  
 
2.3 Reactive oxygen species, cancer and PI3K pathway 
 
Given the broad range of ROS sources and their highly reactive nature, it is 
not surprising that ROS have been implicated in a number of disease like 
neurodegenerative75, 76, 77, cardiovascular diseases78, 79, and cancer49, 80, 81. 
It is known that one of the main features of cancer cells is their extremely high 
level of ROS82, 83, giving them a persistent pro-oxidative state, which ultimately can 
lead to intrinsic oxidative stress. How do these cells survive under such elevated 
baseline ROS levels, and even benefit from them, has been a key question that was 
only recently answered. 
Cancer cells have developed mechanisms to protect themselves from 
intrinsic oxidative stress, by negatively regulating ROS through the increase 
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expression of the antioxidant enzymes67, and activation of redox-sensitive 
transcription factors, including NFκB, HIF-1, and c-jun84, 85, 86, 87, which may contribute 
to cancer cell adaptation to persistent oxidative stress. Higher levels of antioxidant 
enzymes are present in malignant tissues compared with the normal tissue88, 89. 
Thus, it seems that the increase of antioxidant defenses are acquired by cancer cells 
to escape severe oxidative damage and to survive in the presence of intrinsic 
oxidative stress. 
Since cancer cells can produce large amounts of ROS, it has been reported 
that ROS may have a role in cancer initiation, promotion, progression49, 90, and even 
at therapy resistance91, 92, 93. Increased ROS levels contribute to malignancy by 
persistent promotion of cell survival and proliferation, whether by exerting an 
oncogenic stimulation or inhibiting apoptosis91. Doubtless is that ROS can contribute 
to oncogene activation, or act as their downstream effectors94. Not only, enhancing 
the rate of mutations, which leads to DNA damage and chromosomal instability 
contributes to cancer progression95, but also cytoskeletal rearrangements, regulation 
of signaling pathways and transcriptional activities favors the metastatic process 
through cell migration, invasion, and metastization96, 97. The activation of several 
oncogenes, such as the c-myc98, increases generation of ROS and consequently 
DNA damage, interfering with the p53-mediated DNA damage response99, enabling 
cells with damaged genomes to enter the cycle and accelerate tumor progression via 
genetic instability100. Also, metalloproteinases -3, -10, and -13, which are involved in 
the remodeling of extracellular matrix, seem to be upregulated by prolonged H2O2-
induced oxidative stress101. In addition, the transformation of hematopoietic cells by 
the oncogenic tyrosine kinase BCR-ABL is associated with a chronic increase in 
intracellular ROS level of mitochondrial origin102, 103, 104.  
Other than acting at the transcriptional level, ROS can also act at the signal-
transduction level to exert pro-survival functions, by activating several pathways, 
including the Phosphatidylinositol 3-kinase (PI3K)/Akt pathway105, 106, 107, 108. The PI3K 
family is constituted by lipid kinases that phosphorylate the 3’-hydroxyl group of 
phosphoinositides. Within the 3 classes of PI3K109, 110, the class IA PI3K is the 
cancer-related109. PI3K is one of the principal components of the PI3K/Akt signaling 
pathway, and its activation initiates a signal transduction pathway that promotes 
cancer cell growth, metabolism, and survival110, 111, 112. Akt, a serine-threonine kinase 
directly activated in response to PI3K110, is a crucial downstream effector of PI3K in 
tumorigenesis. Due to its well recognized vital importance in cancer cells survival, 
PI3K inhibitors are reaching the clinical field. The activation of this pathway has been 
negatively linked to several type of tumors, where its constitutively activation is 
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correlated with poor prognosis113, 114 and therapy resistance115, 116. PI3K is activated 
by a wide range of upstream signals, including ROS acting as second messengers105, 
106, 107, 73. In acute lymphoblastic leukemia, PI3K pathway activation by IL-7 is 
dependent of ROS upregulation108. Additionally, signaling pathway itself contributes 
to ROS production in order to sustain its own activity. Also, the elevated ROS levels 
of BCR-ABL-expressing cells in chronic myelogenous leukemia contributes to the 
pathway activation, either through the inhibition of PP1α103, conferring a higher 
resistance to apoptosis, or by activation of pathway members such as Akt and 
GSK3β102. Indirect activation of the pathway can be regulated by ROS; ROS can 
inactivate PTEN105, 106, 117, which is a negative regulator of the pathway, driving the 
cells to their pro-survival functions. Therefore, these strong evidences establish that 
PI3K/Akt/mTOR may be redox regulated.  
 
2.4 Oxidative Stress in Glioblastoma: a commitment to resistance 
 
As mention before, oxidative stress has been implicated in GBM radio and 
chemoresistance50; however, the role of ROS in these processes remains unclear. 
Until now, oxidative stress-indissociable ROS production ROS production and 
alterations in the expression of antioxidant enzymes have been implicated with 
cancer cells survival and resistance to anticancer treatment. ROS production by 
enzymes such as NADPH oxidase Nox4, a major non-mitochondrial source of 
ROS61, is associated with the proliferation118 and resistance of glioma cell to 
apoptosis119. The NADPH oxidase Nox4 overexpression in GBM can regulate 
apoptosis evasion through the cascade of antiapoptotic proteins, such as the 
PI3K/Akt pathway, the mTOR, and the NF-κB.120 Contributing to this resistance 
phenomena are the antioxidant enzymes such as, peroxiredoxin II121, catalase and 
glutathione peroxidase 1122, where their overexpression regulate the oxidative stress 
in GBM cells, by mediating resistance to ROS-mediated cell death. This studies 
show that inhibition of these enzymes sensitizes glioma cells to oxidative stress, 
presenting them as potential therapeutic targets. Overall, the search for genetic 
alterations in pro-oxidant enzymes and the knowledge about the antioxidant enzyme 
status of GBM may be useful tools for overcome ROS inducing resistance in GBM. 
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AIMS 
 
General Aim 
 
Emerging studies report that the PI3K pathway may be redox-regulated, 
whether by being activated or contributing to sustain intracellular ROS levels in 
cancer. Since HOXA9 activation is PI3K pathway-dependent, we therefore 
hypothesized that HOXA9 could be one of the effector proteins for ROS upregulation 
in this pathway. So, the overall aim of this thesis is to understand how the PI3K 
pathway-associated generation of ROS may be dependent on HOXA9.  
 
Specific Aims 
 
To meet the main purpose of this thesis, our specific aims are to: 
− Evaluate the influence of HOXA9 in ROS production in GBM cells. 
 
− Investigate the influence of HOXA9 in the response of GBM cells to ROS 
stress. 
 
− Clarify if HOXA9-mediated ROS production is independent of PI3K pathway. 
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MATERIALS AND METHODS 
 
1 Cell Culture !
The in vitro studies comprised the use of three cell lines: the U87MG, the 
A172 (both human GBM-derived cells) and the hTERT/E6/E7 (human astrocytes 
immortalized with the human telomerase reverse transcriptase and with the human 
papillomavirus oncogenes E6 and E7). Both U87MG and the putative GBM precursor 
cell line hTERT/E6/E7 were previously established7 by having a stable 
overexpression of HOXA9 as a result of a retroviral infection with the murine stem 
cell virus (MSCV) encoding HOXA9 (MSCV-HOXA9) or a control vector (MSCV-
Control). Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, from 
Gibco - Invitrogen®) supplemented with 10% fetal bovine serum (FBS, from 
Biochrom AG) and 1% penicillin/streptomycin (100U/ml penicillin, 100 ug/ml 
streptomycin, from Gibco - Invitrogen®). HOXA9 overexpressing cell lines and their 
counterparts were additionally supplemented with 500 µg/ml G418 (Sigma-Aldrich), 
an antibiotic that selects cells containing the neomycine resistance gene present in 
the retroviral construct. The cells were maintained at 37ºC in an incubator with 5% 
CO2.  
2 Induction of Oxidative Stress with H2O2 !
For all oxidative stress measurements, 1 x 106 cells were plated in cell culture 
flasks with 75 cm² surface area and allowed to adhere overnight. Exposure with 
either 1500 µM of H202 or DMEM medium supplemented with 10% FBS (untreated 
control) was carried out from 15 to 30 minutes and from 15 minutes to 4 hours in 
hTERT/E6/E7-HOXA9 and U87MG-HOXA9 as well as in their respective control 
cells, respectively. 
3 Reactive Oxygen Species Quantification 
 
Intracellular ROS generation was determined by measuring the levels of H2O2 
produced in the cells by flow cytometry after staining cells with cell permeable 2', 7'-
dichlorodihydrofluorescein diacetate  (H2DCFDA, from Molecular Probes - Life 
Technologies). After incorporation into cells, H2DCFDA is readily cleaved by 
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esterases and oxidized by ROS to form fluorescent 2', 7'-dichlorofluorescein (DCF). 
Thus, DCF fluorescence estimates ROS generation in living cells. Briefly, the cells 
were washed twice with PBS and then 2,5 x 107 cells were incubated with 5 µM 
H2DCFDA at 37ºC for 25 minutes in the dark. After incubation, cells were washed 
and ressuspended in PBS and analyzed for ROS generation using LSRII flow 
cytometer (BD Biosciences). For all the experiments, approximately 10,000 events 
were evaluated for each sample. ROS levels were calculated by measuring the mean 
fluorescence using FlowJo software (Tree Star, Ashland).  
4 Cell Viability Assays 
 
Metabolic activity was measured using CellTiter 96® AQueous One Solution 
Reagent (Promega Corporation) a (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) compound. The 
measurement of cell metabolic activity is based on the activity of cell 
dehydrogenases and their ability to cleave tetrazolium salts, forming a colored 
formazan product. Briefly, 4x103 cells per well were cultured in 96-well culture plates 
followed by H2O2 exposure for the indicated concentrations and desired time, 
according to experimental purpose. At every time point, 10µl per well of MTS was 
added and incubated at 37ºC for 2 hours. The absorbance was measured on Infinite 
200 NanoQuant microplate reader (Tecan) at 490 nm. Absolute absorbance was 
normalized to the absorbance of untreated cells in each plate and expressed as a 
percentage of the control value. 
Cell viability was also measured using trypan blue exclusion assay 
(Invitrogen, Life Technologies), where non-viable (dead) cells with compromised 
membranes are permeable to the blue staining. Cells were cultured in 6-well culture 
plates with an initial density of 6 x 104 cells per well. After 24 hours of cell plating, 
1500 µM of H2O2 was added in 2 ml of DMEM supplemented with 10% FBS and 
treatment was executed for 4, 8, 24, 48, 72 and 96 hours. At each experimental time 
point, the viable cells were counted in duplicate, using a Neubauer chamber, under 
the IX51 inverted microscope (Olympus). The total number of viable cells was 
calculated using the following: 
 Total cells = mean of viable cells x dilution factor x 1000 cells/ml 
                                                                                    0,1 
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5 Glucose Consumption and Lactate Production 
 
To measure glucose consumption and lactate production, 5 x 104 cells were 
cultured in 24-well plates with overnight adherence. Every 24 hours during 4 days, 
the media was collected and frozen until the time for glucose uptake and lactate 
production quantification. Extracellular lactate quantification was determined using a 
commercial assay kit Lactate Enzymatic colorimetric LO-POD (Spinreact) and 
following the manufacturers’ instructions. Briefly, lactate production was calculated 
by measuring the absorbance (490 – 570 nm) of lactate oxidized by lactate oxidase 
(LO) to pyruvate and H2O2, which under the influence of peroxidase (POD), 4-
aminophenazone and 4-chlorophenol form a red quinone compound. The intensity of 
the color formed is proportional to the lactate concentration in the sample. Glucose 
quantification was performed using an enzymatic colorimetric assay Glucose god-
pap (Roche Diagnostic) based on the conversion of glucose into gluconate by 
glucose oxidase (GOD). The H2O2 produced in the reaction is degraded by POD and 
gives a colored product phenol and 4-aminoantipyrine, which is measurable using 
Trinder indicator reaction at 505 nm. The increase in absorbance correlates with the 
glucose concentration of the sample. All glucose and lactate quantifications were 
normalized to cell biomass by sulphorodamine B (SRB) assay (Sigma-Aldrich), 
where the adherent cells were fixed with 10% trichloroacetic acid for 1 h at 4°C, 
rinsed with water, air-dried and stained with 0.4% SRB for 30 min at 37°C. The 
bound dye was solubilized with 10 mM Tris (100 µl per well) and the absorbance 
measured at 540 nm. 
6 Treatment of Cell Lines with PI-103 
 
The U87MG-HOXA9, hTERT/E6/E7-HOXA9 and their respective control 
cells, as well as the A172 cell line were exposed for 24 hours to 1, 2 and 6 µM of the 
PI3K inhibitor PI-103 (Selleck Chemicals) or DMSO vehicle as control, respectively. 
7 Western Blot 
 
The cell lines under study were scrapped off and washed twice in cold PBS, 
followed by protein extraction. Thirty ug of total protein extract was resolved in 10% 
                                      Influence of HOXA9 expression in the PI3K-mediated oxidative stress in GBM 
! 15!
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), blotted 
onto a nitrocellulose membrane (Amersham™ - GE Healthcare Life Sciences) and 
probed with antibodies raised against Akt and phospho-Akt (p-Akt Ser 473) (1:500; 
Cell Signaling). The secondary antibody was goat anti-mouse IgG-HRP (1:5000; 
Santa Cruz Biotechnologies). Each membrane was re-probed with antibody against 
α-tubulin (1:100; Santa Cruz Biotechnologies) for protein loading control. Detailed 
Western Blot protocol is described in Appendix I. 
8 Quantitative Real-Time PCR 
 
The cell lines were lysed with TRIzol (Life Technologies, Inc) and the isolated 
RNA was reverse transcribed using Reverse Transcriptase (Invitrogen); both total 
RNA extraction and cDNA generation protocols are described at appendix I. HOXA9 
was amplified by qPCR using Kapa™ SYBR ® FAST qPCR Master Mix Kit 
(Kapabiosystems) in parallel with hGUS to use as a control gene for quantification. 
Primers used for quantitative real-time PCR were as follows: HOXA9, 5′-
GGAGATGCTCACTTCGATGA-3′ (sense) and 5′ ATACCCAAAGAATGGCCAAG-3′ 
(antisense); and hGUS, 5′-AGGAGGAGGGCAGAATCATCA-3′ (sense) and 5′-
CTCGATTGGATGGCAGTAGCT-3′ (antisense). The relative quantification of gene 
expression was determined by the equations: ΔCt = (CtHOXA9 – CthGUS) followed by (2-
Δ
Ct)*100 (expressed as percentage). qPCR reactions were performed in triplicate. 
9 Statistical Analysis 
 
To evaluate the trypan blue viability assay’s, glucose uptake and lactate 
production differences, repeated two-way ANOVA measures were used to compare 
each pair of curves along the time. For the rest experimental analyses statistical 
significance was assessed by using the t-test Student’s. The results are expressed 
as mean ± standard deviation (S.D.), and analyzed by GraphPad Prism 7.6 
(GraphPad Software). All experiments were conducted in triplicate and repeated 3 
times. Statistical significant differences were considered when P < 0,05. 
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RESULTS 
1 HOXA9 upregulates intracellular ROS in U87MG GBM cells !
Elevated ROS levels are demonstrated to be associated with cancer58. As 
previously reported, HOXA9 is important for GBM cell viability in vitro, and since 
ROS is related to cancer cell survival, we investigated what would be the influence of 
HOXA9 in ROS production in both GBM-derived cell line and its putative precursors. 
To this purpose, cell lines with frequent confirmation of HOXA9 overexpression by 
RT-PCR (Appendix I and II) were cultured for 15 and 30 minutes for hTERT/E6/E7 
cell line, and for 15 minutes and 24 hours for U87MG, with or without H2O2 treatment. 
Then, intracellular ROS production was evaluated by flow cytometry using 
H2DCFDA. We observed that in basal conditions, U87MG GBM cells that 
overexpressed HOXA9 had a significantly higher accumulation of intracellular ROS 
(Figure 1A), comparing with their control cell line (U87MG-MSCV). Curiously, the 
ROS levels detected in hTERT/E6/E7 cell line overexpressing HOXA9 were 
significantly lower despite the expression of HOXA9 (Figure 1B). 
Furthermore, we aimed to see what would be the effect of exposure of these 
cells to an exogenous source of oxidative stress using a ROS molecule, H2O2. We 
found that treatment with 1500 µM of H2O2 for the same time points caused an 
increase of ROS in all cell lines (hTERT/E6/E7±HOXA9 and U87MG±HOXA9); 
however, different profiles were observed within each cell line. On one hand, the 
U87MG-HOXA9 had an increase of ROS levels of approximately 2- and 1,5 –folds 
for 15 minutes and 24 hours of H2O2 exposure, respectively (Figure 1C). This ROS 
upregulation by HOXA9 overexpressing GBM cells was significantly higher than the 
control cell line, suggesting that HOXA9 may have an influence in intracellular ROS 
production. On the other hand, although both hTERT/E6/E7 cell lines did increase 
the ROS levels upon H2O2 exposure, it was clear that hTERT/E6/E7-HOXA9 cell line 
produced significantly lower levels of ROS comparing to its counterpart (figure 1D). 
These results suggest that HOXA9 do not have a pronounced effect in terms of ROS 
production in the astrocytic lineage. 
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 Overall, these data indicate that treatment with pro-oxidants cause significant 
increases in intracellular levels of ROS in both cell lines. However, ROS production 
by U87MG-HOXA9 was significantly higher compared to the U87MG-MSCV cells; on 
the contrary, it was markedly lower for hTERT/E6/E7-HOXA9 in relation to its control 
cell line. 
Figure 3. HOXA9 overexpression enhances ROS production in U87MG GBM 
cells. ROS production was estimated by oxidation of the fluorescent probe, 
H2DCFDA in (A) U87MG and (B) hTER/E6/E6 cell lines after indicated time of 
treatment with vehicle (control) or H2O2 (1500 µM). Ratio of intracellular ROS 
production between H2O2 and control conditions was determined for (C) U87MG and 
(D) hTERT/E6/E7 cell lines. *P < 0,05; **P < 0,01. 
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2 HOXA9 mediates a metabolic shift in U87MG GBM cells 
 
The high production of ROS by U87MG-HOXA9 cells may reflect a lower 
glycolytic rate. To test this hypothesis, we investigated the metabolism of each cell 
line by measuring the glucose uptake and lactate production. By these assays, it is 
possible to see that both cell lines, the U87MG (Figure 2A) and hTERT/E6/E7 
(Figure 2B), presented higher glucose consumption in HOXA9-overexpressing cells, 
when compared to the control MSCV-cells. However, only the hTERT/E6/E7 cell 
lines presented statistical significant difference over time (P= 0,0187), while the 
U87MG cell lines only showed statistical significant difference in the 4th day (P= 
0,0015). When looking to the lactate production, it is clear that there is a difference 
between cell lines; the U87MG-HOXA9 cell line produces less lactate (Figure 2C) 
than its HOXA9-negative counterpart, and therefore is less glycolytic. On day 4, the 
cells from the U87MG-MSCV line were not completely attached to the plate surface, 
which affected SRB assay, and, ultimately decreased lactate production. In this 
sense, it was not possible to obtain statistical significant differences between the 
U87MG-HOXA9 and U87MG-MSCV. However, statistically significance was reached 
in the 3th day (P= 0,0076). On the contrary, the lactate production by the 
hTERT/E6/E7-HOXA9 cell line was higher (Figure 2D) comparing to their control 
cells along the time (P= 0,0013). 
Overall, the metabolism of the cell lines under study is in agreement with the 
reported metabolic program of cancer cells by Otto Warburg. However, some are 
more glycolytic than others. The lower glycolytic profile of U87MG-HOXA9 is 
suggestive of an increased oxidative phosphorylation to satisfy its energetic 
demands, which is consistent with our previous data regarding ROS upregulation by 
U87MG GBM HOXA9-overexpressing cells. 
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Figure 4. HOXA9 overexpression is associated with reduced glycolytic status 
in U87MG GBM cells. Quantification of (A) glucose uptake and (C) lactate 
production in U87MG cell lines. (B) Glucose uptake and (D) lactate production in 
hTERT/E6/E7 cell lines. #, *P < 0,05; ##, **P < 0,01. 
 
3 HOXA9 influences the viability of U87MG GBM cells after oxidative stress !
Knowing that ROS could either be exerting beneficial or compromising effects 
on cancer cells, we investigated how HOXA9-mediated upregulation of ROS may 
affect cellular response, specifically cell viability. A range of H2O2 concentrations 
(500, 1500 and 3000 µM) were used to treat cells for 24 hours and evaluate their 
response under such oxidative stress. 
By the MTS assay, it is clear that both cell lines, the U87MG and 
hTERT/E6/E7 (Figure 3A and B, respectively) were not tolerant to this extremely 
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oxidative stress driven by H2O2, resulting in an accentuated decrease on cellular 
metabolic activity. However, the U87MG-HOXA9 cell line (Figure 3A) remarkably 
maintained its normal metabolic activity until the H2O2 concentration of 1500 µM, 
from which began to decrease cell metabolic viability. This result evidenciate that 
HOXA9 mediates cell resistance to oxidative stress in GBM-derived cells.  
Figure 5. Viability of HOXA9 overexpressing cells is H2O2 dose-dependent. 
Determination of cellular metabolic viability by MTS assay performed in GBM-derived 
cell line (A) U87MG and in (B) astrocytic cell line hTERT/E6/E7. Both lines were 
treated with or without H2O2 for 24 hours. ***P = 0,0002. 
 
This result really escalated the interest to evaluate the response of both cell 
lines to the same H2O2 concentration along the time. To assess this, cells were 
treated with 1500 µM of H2O2 for 4, 8, 24, 48, 72 and 96 hours. The trypan blue 
assay results show that in basal conditions, both U87MG-HOXA9 (Figure 4A) and 
hTERT/E6/E7-HOXA9 (Figure 4B) cell lines presented a significant increase in cell 
viability (P= 0,0170 and P < 0,0001, respectively), when compared to the control 
MSCV-cells. Under H2O2 treatment, only GBM cells with HOXA9-overexpression 
(Figure 4A) demonstrated higher viability comparing to their counterpart (P= 0,0045); 
while the hTERT/E6/E7 cell line (Figure 4B) did not present differences between 
HOXA9-overexpressing cells and their control cells, being their viability extremely 
affected along the time. A similar reduction in cell viability after 4 and 8 hours of 
exposure to H2O2 was observed in both cell lines. However, U87MG-HOXA9 cells 
presented a notably recovery of their cell viability along the time, compared to the 
control MSCV-cells. This result indicates that HOXA9 may play an important role in 
oxidative stress resistance in GBM-derived cells. 
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 Figure 6. HOXA9 overexpression confers resistance to oxidative stress in 
U87MG GBM cells. Trypan blue cell viability assay was executed in (A) U87MG and 
(B) hTERT/E6/E7 cell lines. Cell lines were treated with or without H2O2 for the 
indicated time. Effect of H2O2 compared with untreated cells: *P < 0,05; ***P < 0,001. 
 
Similar results were observed in a different approach to analyze cell viability 
using the MTS assay. In the same experimental conditions as used in the previous 
assay, the ratio of cell metabolic viability between H2O2-treated and untreated cells 
was outlined for both cell lines. For the first 4 hours of H2O2 exposure, in the U87MG 
cell line (Figure 5A) it is noted that although there was a decrease of 40% and 70% 
for HOXA9 overexpressing cells and their HOXA9-negative controls, respectively, 
HOXA9 expression seems to mediate a metabolic viability recovery until the end of 
the experiment. Also, the HOXA9-overexpressing cells demonstrate a statistical 
significant higher metabolic activity than the MSCV-Control cells across the time (P ≤ 
0.0001 for 4, 8, 24 and 72 hours, and P= 0,0003, P= 0,0043 for 48 and 96 hours, 
respectively). When comparing the metabolic activity of the hTERT/E6/E7 (Figure 
5B) it significantly decreased its metabolic activity down to 70% - 75%, with absence 
of a visible recover along the time. In addition, the HOXA9-overexpressing cells 
demonstrate a significant lower metabolic activity than the MSCV-Control cells (P= 
0,0011, P= 0,0101, and P=0,0080 for 4, 8 and 24 hours, respectively). At 96 hours it 
was a statistically significant inversion of this behavior (P = 0,0249).  
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Figure 7. HOXA9 overexpression influences cellular metabolic viability. 
Metabolic viability of (A) U87MG and (B) hTERT/E6/E7 cell lines was determined by 
the MTS assay. Cell lines were treated with or without H2O2 for the indicated time. 
Effect of H2O2 compared with untreated cells: *P < 0,05; **P < 0,01; ***P < 0.0001. 
 
4 Inhibition of PI3K pathway does not impair ROS production in HOXA9 
overexpressing cells. 
 
To further explore the consequence of inhibition of PI3K pathway regarding ROS 
production in our cell models, an inhibitor of this pathway, PI-103, was used for 24 
hours with different concentrations according to the cell line. Because Akt is a 
downstream effector of PI3K pathway, contributing for the activation of several 
molecules, we first determined the status of p-Akt and total Akt by immunobloting the 
cell lysates against these proteins. In U87MG and hTERT/E6/E7 cell lines, treatment 
with 1 µM and 2 µM of PI-103, respectively, decreased phosphorylation of Akt (figure 
8 A and B, respectively). This result is indicative of a partial inactivation of PI3K/Akt 
signaling pathway. Additional studies using a different cell line, the A172, which is 
reported to express HOXA9 endogenously32 showed a completely inhibition of 
PI3K/Akt pathway (Figure 8C). 
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Figure 8. PI-103 suppresses PI3K pathway through Akt phosphorylation. 
Western blot analyses of (A) U87MG, (B) hTERT/E6/E7 and (C) A172 cell lines. All 
cell lines were treated with control (DMSO) or with PI-103 for 24 hours. 
 
Since, the activation of PI3K/Akt signaling pathway is crucial for HOXA9 
activation in GBM cells32, the expression of HOXA9 upon inhibition of p-Akt by PI-103 
was evaluated by qRT-PCR. The results show that inhibition of p-Akt significantly 
reduced the levels of HOXA9 expression in all cell lines (Figure 9A, B and C), even 
those that exogenously overexpress HOXA9. The inhibitory effect of PI-103 in 
HOXA9 expression reached statistical significance in all the three cell lines, with P = 
(0,0031; 0,0101; 0,0085) for U87MG-HOXA9, hTERT/E6/E7-HOXA9, and A172, 
respectively. 
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Figure 9. Suppression of PI3K activity reduces HOXA9 expression. The effect of 
PI-103 on expression levels of HOXA9 was determined by qRT-PCR for the (A) 
U87MG, (B) hTERT/E6/E7, and (C) A172. Effect of PI-103 compared with DMSO: *P 
< 0.05; **P < 0.01. 
 
Regardless the HOXA9 expression have an endogenous or exogenous 
origin, the inhibition of PI3K/Akt pathway reduced its expression. Knowing this, it was 
investigated if it would affect ROS production. For this, the same experimental 
conditions for each cell line were kept, and intracellular ROS levels were measured 
in all the cell lines. Firstly, using the A172 cell line in which its known that HOXA9 
expression relies on PI3K/Akt pathway activation, it was showed that in the 
deprivation of HOXA9 activation through PI3K/Akt signaling inhibition it impaired 
ROS production (Figure 10C, P = 0,0309). In the other cell lines with exogenous 
HOXA9 expression it was observed that the inhibition of PI3K/Akt signaling did 
significantly increase the levels of ROS (P= 0,0376) in the U87MG-HOXA9 cells 
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(Figure 10A), standing these cells with a major ROS upregulatory effect. On the 
contrary, the U87MG-MSCV (Figure 10A) and the hTERT/E6/E7-HOXA9 (Figure 
10B) cell lines did not show alterations in ROS levels after PI-103 treatment. It was 
also noted the significant ROS decrease in the hTERT/E6/E7-MSCV cell line (P = 
0,0093). 
Figure 10. Exogenous HOXA9 expression in U87MG GBM cells increases ROS 
production after PI-103 treatment. Total ROS production was measured in (A) 
U87MG, (B) hTER/E6/E7, and (C) A172 cell lines after PI-103 exposure. *P < 0,05; 
**P < 0,01. 
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DISCUSSION 
 
Due to the urge necessity to find biomarkers with a prognostic value for 
patients facing GBM disease, recent studies raised interested in the study of HOX 
genes, already shown to be abnormally expressed in GBM31, 32, 33. From all HOX 
genes, some from the cluster HOXA, especially HOXA9 were reported to be 
overexpressed in GBMs32. Latter studies demonstrated that HOXA9 aberrantly 
expression in GBM primary tumors is associated with shorter overall and 
progression-free survival for GBM patients32. It was also reported that the 
transcriptional activation of HOXA9 in GBM is PI3K-dependent32. Given the 
extensively reported importance of PI3K pathway in cancer survival, recent studies 
associate this pathway with ROS production105 - 108, indicating that it could be redox 
regulated. With the intent to deliver more understanding about HOXA9 role in GBM, 
this work aimed to evaluate the effect of HOXA9 regarding ROS production in GBMs.    
In the U87MG GBM cells, it was found that cells with HOXA9 overexpression 
produced ROS up to levels that were higher than the control cells lacking HOXA9 
expression. Cancer cells are well known to be under intrinsic oxidative stress82, 83, 
which depending on the levels could act as a stimuli for promotion of proliferation, 
migration and invasion49, 90. In a previous study, HOXA9 was established as a novel 
prognostic factor with negative value32, most probably due to its capacity to enhance 
proliferation and evade apoptosis, where ROS can be contributing to this tumorigenic 
phenotype, by its elevated levels. To be true, this relation was found to be possible 
only in U87MG-HOXA9 cells; their putative precursors, the human immortalized 
astrocytes, did not present an elevation of ROS generation even in the presence of 
HOXA9, which levels were intriguingly lower compared to the control cells. This 
result is indicative that HOXA9 and the way it mediates the production of ROS is 
dependent of the cell lines and their inherent aggressiveness. Additionally to these 
findings it was important to assess the metabolism features of these cells lines. One 
of the reasons by which cancer cells rely their energetic demands on enhanced 
aerobic glycolysis, also known as Warburg effect123, is to limit ROS levels124 that can 
be harmful for the cells. This metabolic hallmark of cancer cells was extended to the 
current study, where the enhanced aerobic glycolysis presented by human 
immortalized astrocytes with HOXA9 overexpression strongly supported the 
principles of Warburg effect; a higher lactate production that as been described to act 
as a ROS scavenger125 is associated with a lower production of ROS. This analysis 
                                      Influence of HOXA9 expression in the PI3K-mediated oxidative stress in GBM 
! 27!
also linked the high rates of ROS production in GBM-derived cells with HOXA9 
overexpression with their lower glycolytic status, suggesting a preference for the 
oxidative metabolic pathway. These evidences are indicative that HOXA9 may be 
regulating cell metabolism in GBM cells towards mitochondrial phosphorylation in 
order to upregulate ROS production to achieve a major goal: continuous stimulation 
of pro-survival factor within survival pathways, like PI3K. Submitting the cells to 
oxidative stress by using an exogenous source of ROS, H2O2, was the next rational 
step with the purpose to look at their intracellular ROS behavior. As expected, both 
cell lines, with or without HOXA9 expression presented an increase of ROS 
production after challenges with H2O2. The apparent non-alteration of ROS levels 
upon oxidative stress stimuli in both cell lines of the astrocytic lineage model is 
suggestive that these cells may have an anti-oxidant system widely activated. 
However, the main message is that HOXA9 upregulates ROS production in GBM-
derived cells. The HOXA9 capacity to upregulate ROS in GBM cells, was found to 
affect cell viability; however, these cells present a resistance profile, which make 
them capable of recovering, even the presence of such oxidative stress. So, these 
evidences suggest that HOXA9 overexpression confers resistance to oxidative stress 
in GBM cell line, and as previous mention this ROS are the way by which HOXA9 
promotes cell proliferation and evasion to apoptosis. Is to discover the mechanism by 
which these cells resist to such oxidative stress. The literature often reports that 
cancer cells have higher levels of antioxidant enzymes67 which balance ROS levels 
to levels that are tolerated by the cells, and that level vary from cell type to cancer 
type and aggressiveness. Opposite observations were made in the hTER/E6/E7 cell 
line, where HOXA9 did not seem to play an important role in H2O2 resistance, which 
is probably the reason why this cells do not produce high levels of ROS due to the 
inability to tolerate excessive oxidative stress. 
As previously described, in leukemia PI3K was found be responsible for 
elevated levels of ROS 102, 103, 105, 108. Therefore, the final part of the project focused 
on investigating the effect of the inhibition of PI3K pathway on ROS production and 
ultimately, to unveil if HOXA9-mediated ROS production is independent of PI3K 
pathway. PI-103, a dual inhibitor of PI3K (upstream of Akt) and mTOR (downstream 
of Akt) has been reported to inhibit human glioma cells126, 127. Contrarily to reported in 
leukemia108, PI-103 treatment and subsequent acceptable inhibition of PI3K signaling 
did not decrease ROS levels in U87MG-HOXA9 cells; on the contrary, it increased 
ROS levels when compared to the control DMSO treatment group. The same was 
not valid for the U87MG-MSCV cell line, where PI-103 did not alter ROS production. 
                                      Influence of HOXA9 expression in the PI3K-mediated oxidative stress in GBM 
! 28!
This result showed that ROS production by U87MG cell line seems to be 
independent of PI3K pathway, suggesting that HOXA9 may have an outstanding role 
in this process. Further studies were needed to elucidate the HOXA9 contribution for 
ROS generation in the pathway. To dissect this hypothesis, in the other way around, 
was used the A172 cell line with endogenous expression of HOXA9, proven to be 
dependent on PI3K/Akt signaling pathway for its transcriptional activation32. As 
theoretically expected, inhibition of the PI3K/Akt pathway decreased HOXA9 
expression and intracellular ROS. The results from the qRT-PCR for the cells with 
HOXA9 overexpression revealed that HOXA9, even though exogenously expressed, 
it is somehow regulated by the PI3K or by PI-103; where after PI-103 treatment the 
HOXA9 expression levels significantly decreased in both HOXA9 overexpressing cell 
lines. A reasonable explanation for the reduction of HOXA9 expression upon 
inhibition of PI3K/Akt pathway is that this pathway could be regulating HOXA9 
expression. By the fact that HOXA9 expression was retroviral-induced, it does not 
exclude that its overexpression can not benefit from the PI3K regulatory activity. 
Actually, since this pathway regulates several other signaling molecules, it is 
reasonable to think that they could be afecting HOXA9 expression trhough activating 
transcription factors that regulates HOXA9 inside the retroviral construct. Another 
hypothesis that can deliver more understanding about this results, is the unknown 
effect of PI-103 on HOXA9 expression. Apart from specific inhibition of PI3K isoforms 
but also of the phosphoinositide kinase family of proteins, there is not known the 
effect of PI-103 on other molecules; probably, PI-103 can interact with HOXA9 by 
inhibiting it. At this point, its not possible to confirm the HOXA9 role mediating ROS 
production in GBM cell lines independently of the PI3K pathway; however, these 
preliminary results suggest that HOXA9 can be regulating ROS independently of 
PI3K/Akt signaling pathway, but dependently of cancer cell aggressiveness. 
Importantly, is the fact that HOXA9 is implicated in ROS production in GBM. To 
discover are exact role of ROS mediated by HOXA9 in GBM. 
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CONCLUSIONS 
 
This work reports the first study about the contribution of HOXA9 in redox 
regulation of GBM disease and the contribution of PI3K pathway for ROS production 
in GBM. Establishing a rational in all the data from this thesis, it possible to conclude 
that the studied U87MG GBM cell line with HOXA9 overexpression upregulated 
intracellular ROS, in basal and in oxidative stress conditions. This elevated oxidative 
stress translated into a moderated decrease of cell viability, but with the twist that 
these cells show a resistance phenotype by recovering their viability over the time. 
Not only, these cells are capable to resist to oxidative stress but also, under it they 
continuously presented elevated ROS levels. Maybe to promote cell proliferation 
through ROS production, HOXA9 mediates a metabolic shift in GBM cells from 
aerobic glycolysis towards mitochondrial oxidative phosphorylation. We strengthened 
the role of HOXA9 in ROS production, dependently or independently of PI3K 
pathway, in GBM context. We also deliver some additional information about the fact 
that HOXA9 effects can be dependent on the cell context; the conjecture of 
characteristic malignancy and aggressiveness of the tumor cells may enhance 
HOXA9 effect in ROS production. This opens new challenging opportunities to 
explore the relevance of ROS upregulation by HOXA9 in the GBM resistance to 
therapy. 
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FUTURE DIRECTIONS 
 
The results presented in this work favor future approaches to elucidate the 
role of HOXA9 in ROS production in GBM. 
Given the PI-103 results regarding HOXA9 expression, it is essential to 
complement the data obtained by a direct targeting of HOXA9, other then using a 
chemical inhibition. Therefore, the silencing of HOXA9 by siRNA will be performed in 
the A172 cell line to validate the contribution of HOXA9 in ROS production, where we 
anticipate that silencing of HOXA9 will decrease ROS production, and to assess the 
hypothesis whether HOXA9 is the key mediator of ROS production in the PI3K 
pathway. Also, to known the impact of ROS production by HOXA9 overexpression in 
GBM cells, we intent to treat cell lines with an antioxidant, for instance, glutathione or 
N-acetyl-cysteine, and assess the effects of HOXA9-mediated ROS effects on cell 
survival and proliferation. 
Regarding the lower lactate production and therefore a less use of glycolysis 
by U87MG-HOXA9 GBM cell line, which probably reflects a high oxidative 
phosphorylation rate associated with the increase of ROS, further studies are needed 
to confirm the preference of HOXA9 positive cells for the oxidative pathway. To 
assess this, it will be evaluated the expression at the protein level of key glycolytic 
and oxidative phosphorylation proteins, such as lactate dehydrogenase, pyruvate 
dehydrogenase, pyruvate dehydrogenase kinase, and proteins from the 
mitochondrial ETC. From these studies, it will be also evaluated if mitochondrial ETC 
proteins, mainly from the complex I, act as a source of ROS production mediated by 
HOXA9 overexpression. Additionally, a chemical inhibition of this complex I by 
rotenone will allow to confirm the relationship between mitochondrial ROS mediated 
by HOXA9 expression. 
Although HOXA9 overexpressing GBM cells appear to upregulate ROS, it is 
unclear the physiologic functions of these ROS: whether they act as pro-proliferative 
or pro-apoptotic stimulus. To assess this, it will be evaluated the expression status of 
pro-apoptotic proteins such as BAX, caspase – 3, – 7 and – 9, and anti-apoptotic 
proteins like Bcl-2 and PARP. Independently of the conclusions about ROS 
functions, it is necessary to discover the reasons behind the resistance mediated by 
HOXA9 in GBM cells. The most probable hypothesis is that such resistance could be 
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due to the antioxidant system, which limit deleterious levels of oxidative stress. To 
bridge this gap it will investigate the antioxidant enzymes, such as SOD, glutathione 
and peroxiredoxin that are expected to be protecting cells from excessive ROS-
associated damage that could lead to cell death. Maybe, HOXA9 is regulating the 
antioxidant system in order to act when ROS levels are exceeded until beneficial 
ROS levels to these cells are restored. If valid, this could represent other studies in 
order to assess the therapeutic benefit of the inhibition of antioxidant enzymes.  
Since chemoresistance is a severe limitation to TMZ therapy and that TMZ 
methylates nuclear DNA and induces apoptotic cell death through unbalanced ROS 
production, it will be evaluate the potential involvement of HOXA9 in the response of 
GBM to ROS-inducing agents, particularly TMZ. 
It is expected that together, the proposed complementary studies will greatly 
extend insights of the redox regulation mediated by HOXA9 and its impact in GBM. 
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APPENDIXES 
 
APPENDIX I 
 
WESTERN BLOT 
 
Preparation of cell lysates and protein quantification 
After removing the cells from the flasks by using a scrapper, cells where 
washed twice in cold PBS by two consecutive centrifugations at 900 rpm for 5 
minutes at 4ºC, with subsequent PBS discard. Then cell lysates were prepared by 
solubilizing cells in ice-cold lysis buffer (to 100 µl of lysis buffer 1x (50 mM Tris-HCl, 
50 mM NaCl, 5 mM EDTA) was added 1 µl of 100 mM PMSF, 3 µl of proteinase 
inhibitor 25 x and 1 µl of Nonidet®P40) at approximately 0,5 ml per 5x107 cells/60mm 
dish/75cm2 flask. During the 1 hour incubation, the cell suspension was vortexed 3 
times, followed by centrifugation at 13,000 rpm for 10 minutes at 4ºC. The 
supernatant, which contains the cell lysate, was transferred to a new tube and the 
pellet was discarded. 
The total protein concentration of the samples was measured by using the 
Bradford Reagent (Bio-Rad). In polystyrene cuvettes were added 1 µl lysates 
samples plus 200 µl Bradford Reagent and 800 µl of ultra-pure water and incubation 
was allowed for 5 minutes at RT. After blank the spectrophotometer with the lysis 
buffer (1 µl lysates samples plus 200 µl Bradford Reagent and 800 µl of ultra-pure 
water) at 595 nm, the samples absorbance was read. The protein concentration of 
the sample is determined by comparison with the values from a standard curve of 
absorbance. An equal volume of 4X Laemmli buffer was added to all samples (30 µg 
of protein). Prior to protein separation by electrophoresis, the samples were boiled 
for 5 minutes. 
SDS-PAGE  
After the Western Blot system was prepared with confirmation that the system 
was watertight, the preparation of the gels, resolving and stacking gel was carried 
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out. Immediately after of gel preparation was added 50 µl of APS and 5 µl of TEMED 
to the 5 ml of resolving gel (10%), and the final mixture was placed inside of the 
glass frame. Water was added on top of the resolving mixture and discarded when 
the mixture reaches full polymerization. Next, the 20 µl of APS and 2 µl of TEMED to 
the 2 ml of stacking gel (4%), and the mixture was placed on the top of the resolving 
gel. The desired combs were placed on the top of the stacking gel. After complete 
polymerization, the structure that contains the gel was transferred to the running tank 
covered by the cold running buffer. Samples and 5 µl of protein ladder (Novex® 
Sharp Protein Standard, from Invitrogen) were loaded into the wells of the gel, 
followed by the initial electrophoresis run at 80v until the samples reached the 
resolving gel (approximately 20 minutes). Than, the voltage was increased to 100v 
until the bromophenol blue in the samples reaches the bottom of the gel 
(approximately 1 hour). 
Semi-Dry Transfer 
After protein separation, the gel content was transferred to a nitrocellulose 
membrane. The transfer materials were stacked in the following order: 3 Whatman 
papers (8x6cm) + membrane (8x6cm) + gel + 3 Whatman papers (8x6cm) on top of 
the semi-dry transfer system; all pre-wet in cold transfer buffer for 5 minutes. The 
proteins were transferred for 1 hour at 12v. After transfer, the membrane was stained 
with 0.1% Ponceau S for 1-2 minutes to visualize protein bands. Ponceau S was 
removed with cold PBS until the bands disappear. 
Protein blotting 
Unspecific protein receptors where blocked in 5% non-fat dry milk dissolved 
in PBS-Tween 20 (0.1%). Incubation was performed for 1 hour with agitation. 
Afterwards, the membrane was incubated overnight with the primary antibody at 4ºC 
(2.5 % milk in PBS-T for total Akt and 2.5 % milk in TBS-T for p-Akt). After 
incubation, the blocking solution was removed from the membrane by washing 3 
times for 10 minutes with agitation in 1% milk in PBS/TBS-T, followed by the 
incubation with secondary antibody anti-mouse (2.5% milk in PBS/TBS-T) for 1 hour 
at RT. Additional 3 washes with PBS/TBS-T with agitation was executed, changing 
the wash buffer every 10 minutes. 
The membrane was exposed to 400 µl of detection solution SuperSignal 
®West Femto or Pico (Thermo Scientific), and antibodies were then visualized using 
                                      Influence of HOXA9 expression in the PI3K-mediated oxidative stress in GBM 
! 44!
the Chemidoc XRS software (Bio-Rad). The same procedure was performed to the 
control protein, α-tubulin. 
 
RNA ISOLATION FROM CELL CULTURES (TRIZOL) 
 
Homogenization 
Pellet cells by centrifugation at 900 rpm at 4ºC for 5 minutes with 2 
subsequent wash in cold PBS. Per each 5-10 x 106 of cells was added 1 ml of the 
TRIZOL Reagent and allowed cell lysis by repetitive pipetting (pipet up and down 
several times.). The total volume was transferred to a 1,5 ml tube. 
Phase Separation 
In order to achieve complete dissociation of the nucleoprotein complexes, the 
samples were vortexed for 1 minute followed by incubated for 5 minutes at room 
temperature (RT). A volume of 0,2 ml of chloroform was added (0,2 ml of chloroform 
per 1 ml of TRIZOL Reagent), and the samples were hand shaken vigorously until a 
turbidity of the color pink was observed (approximately 15 seconds). After incubation 
of 5 minutes at RT, the samples were centrifuged at 13,000 rpm for 15 minutes at 
4ºC. The centrifugation allowed the mixture to separate into a lower red, phenol-
chloroform phase, an interphase, and a colorless upper aqueous phase. RNA 
remains exclusively in the aqueous phase, where it was transferred to a fresh tube, 
and stored at 4ºC. 
RNA precipitation 
The RNA was precipitated from the aqueous phase by mixing with 0.5 ml 
isopropyl alcohol (0.5 ml of isopropyl alcohol per 1 ml of TRIZOL Reagent used for 
the initial homogenization). Precipitation was carried out during 10 minutes 
incubation at RT. Next, the samples were centrifuged at 13,000 rpm for 10 minutes at 
4ºC. (The RNA precipitate, often invisible  before centrifugation, forms a gel-like 
pellet on the side and bottom of the tube). The supernatant was completely 
discarded. 
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RNA wash 
The RNA pellet was washed once by adding 1 ml of 75%  ethanol (1 ml of 
75%  ethanol per 1 ml of TRIZOL Reagent used for the initial homogenization). The 
samples were mixed by vortexing (10 seconds) and centrifuged at 8,600 rpm for 5 
minutes at 4ºC. The supernatant was removed. 
RNA quantification 
At the end of procedure, it was ensured that the RNA pellet was air-dried for 
10 minutes in an open tube in order not to affect its solubility. Finally, RNA was 
dissolved in 20-50 µl RNase-free water  (dependent on RNA pellet) by passing the 
solution a few times through a pipette tip. RNA quantification for measuring its 
concentration and purity was carried out in NanoDrop ND-1000 spectrophotometer 
(Invitrogen). 
 
cDNA SYNTHESIS 
The cDNA synthesis from cell lines’ RNA was performed using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). To 10 µl of reverse 
transcription master mix (2 µl of 10✕ RT buffer, 0,8 µl of 25✕ dNTP mix (100 mM), 2 
µl of 10✕ RT random primers, 1 µl MultiScribeTM  reverse transcriptase and 4,2 µl of 
nuclease-free H2O) was added 10 µl of RNA sample (2 µg of total RNA per 20 µL 
reaction). A total of 20 µl final volume was obtained, which was submitted to posterior 
synthesis. The thermal cycler conditions were as follows: primer extension at 25ºC 
for 10 minutes, cDNA synthesis at 37ºC for 120 minutes, reaction ending at 85ºC for 
5 minutes and cooled at 4ºC. After synthesis, the 20 µl of cDNA were stored at -
20ºC. 
 
HOXA9 RT-PCR 
For technical control of HOXA9 overexpression in the retroviral infected cell 
lines, its expression was assess by RT-PCR. For 1 µl of cDNA sample a mix of 2.5 µl 
of AmpliTaq Gold Buffer 10 x, 1.5 µl of MgCl2 at 25 mM, 0.5 µl of dNTP mix at 10 
mM, 1µl of HOXA9 primers (20 mM) (forward 5’ – GCCCGTGCAGCTTCCAGTCC – 
3’ and reverse 5’ – GAGCGCGCATGAAGCCAGTTG – 3’), 0.2 µl of Amplitaq Gold 
                                      Influence of HOXA9 expression in the PI3K-mediated oxidative stress in GBM 
! 46!
enzyme and, water to a final volume of 25 µl was added. Samples were amplified in 
a thermal cycler with the following conditions: 4 minutes at 95ºC, 35 cycles of (30 
seconds at 94ºC, 30 seconds at 61ºC, 30 seconds at 72ºC), and 8 minutes at 72ºC. 
Finally, RT-PCR products were resolved 2% of agarose gel, and the bands quantified 
using Alphaimager software (Alpha Innotech Corporation). 
 
 
APPENDIX II 
 
 
 
 
 
 
 
Figure 11 - RT-PCR control for HOXA9 expression in engineered hTERT/E6/E7 
and U87MG cell lines. Both hTERT/E6/E7-HOXA9 and U87MG-HOXA9 cell lines 
show HOXA9 expression (289 bp band), while their respective control cells, 
hTERT/E6/E7-MSCV and U87MG-MSCV, do not show any visible band. Water was 
included for the negative control. 
 
